INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder that affects between 5,000 and 10,000 children and adolescents in the US, and neuropsychiatric manifestations are a common cause of significant morbidity in this population. The American College of Rheumatology criteria recognize only two neuropsychiatric syndromes associated with pediatric SLE: seizures and psychosis. 1 Neurocognitive impairment (NCI), however, is thought to affect as many as 59% of children and adolescents with SLE, 2-4 which is similar to the prevalence seen in adult SLE populations. 5, 6 Differences in study design, including variability in measures of cognitive function and definitions of impairment, the lack of appropriate control groups, and the absence of large-scale prospective studies in pediatric SLE preclude precise estimates of the incidence of NCI. Nonetheless, it is clear that a significant proportion of children with SLE suffer from cognitive difficulties.
Available data from adult and pediatric studies suggest that demographic factors, such as ethnicity, are not predictive of NCI in patients with SLE. Furthermore, NCI can develop in the apparent absence of SLE disease activity or other manifestations of neuropsychiatric SLE. 7 Although comorbid affective disorders might have a role in cognitive complaints, most studies of adults with SLE have not found a significant association between NCI and current symptoms of depression or anxiety. [8] [9] [10] Corticosteroids are frequently used for the treatment of SLE, and are known for their potential to cause psychiatric adverse effects. Studies of adults with SLE have shown mixed results regarding the relationship between steroids and NCI, although most studies suggest no significant relationship. 7, [11] [12] [13] In addition, several studies of adults with SLE suggest a relationship between circulating anti-phospholipid antibodies and the presence or extent of NCI. Pediatric studies, however, have not consistently replicated these findings, instead showing associations between antiphospholipid antibodies and chorea or focal ischemic events. 14, 15 This Review incorporates the findings of several adult SLE studies, as there is a deficit of available data in pediatric SLE specifically addressing NCI. Adult data are not easily extrapolated to children, however, as neurocognitive development in children and adolescents is a fluid process, and environmental and diseaserelated factors also have unique effects on neurocognitive function in pediatric SLE. Recent and ongoing studies in pediatric SLE are highlighted, and an outline of future directions for study of this important problem in children and adolescents is provided.
PATTERNS OF NCI
To date, no consistent pattern of NCI has emerged in assessments of adults with SLE, and the degree of impairment can range from mild or subclinical findings to severe dementia. Abnormalities in processing speed, verbal memory, working memory, visuospatial learning and attention are often reported. 10, [16] [17] [18] The limited data available regarding patterns of NCI in pediatric SLE suggest that these patients have difficulties with complex problem solving, working memory, verbal memory, attention and visuomotor integration. 19, 4, 20 The marked diversity in cognitive problems identified in SLE is likely to reflect the heterogeneous underlying pathophysiology of neuropsychiatric manifestations of the disease.
COGNITIvE DEvELOPMENT IN HEALTHY CHILDREN AND ADOLESCENTS
Cognitive development is complex in healthy individuals, and children and adolescents with SLE are at risk of perturbations of this process. The number of neurons and synapses in the human brain peaks at 2 years of age, following a period of pruning of existing neurons. Continued growth in brain mass after 2 years of age represents an increase in glial cells and proliferation of existing cells; by 5 years, neuronal development is nearly complete. 21 In contrast, myelination is a longer, slower process that continues well into the second or third decade of life. The extent of nerve fiber myelination correlates with the maturation of motivation, attitudes, executive function and frontal lobe functions, all of which are necessary for adult behavior. 22 Mature adult performance for the domains of processing speed, voluntary control of inappropriate behavior, and working memory becomes evident between 14 and 19 years of age. 23 Cognitive development, therefore, is not complete until late adolescence or early adulthood. 24 This critical cognitive maturation period from late childhood through adolescence and into young adulthood coincides with the age spike for pediatric SLE onset, and could also reflect a period of exceptional vulnerability of the central nervous system (CNS). 25 As a result, children and adolescents are at risk of delays and impairments in cognitive development.
PATHOGENESIS OF NCI IN SLE
Although the exact mechanisms underlying the pathogenesis of NCI in SLE remain unknown, autoantibodies and cytokines are likely to have key roles in mediating CNS damage via thrombosis, vasculopathy, inflammation and neuronal cell death. Autopsy studies in neuropsychiatric SLE are small and few, but often show bland smallvessel vasculopathy and a surprising absence of inflammatory changes. 26, 27 The generalizability LEvY ET AL. fEbRUARY 2009 vOL 5 nO 2 www.nature.com/clinicalpractice/rheum of these neuropathologic studies is limited by their bias toward more-severe cases and lack of temporal relationship to clinical events.
Several autoantibodies have been linked to NCI in adults and children with SLE (Box 1); among these, the most common are antineuronal, anti-phospholipid, lymphotoxic and anti-NR2 antibodies. Anti-neuronal antibodies in both the serum and cerebrospinal fluid (CSF) have been implicated in adult neuropsychiatric SLE; however, studies have not focused specifically on NCI or children with SLE, and the results have been mixed. 28, 29 A review of data from small studies suggests a link between lymphotoxic antibodies and cognitive impairment in adults with SLE. 30 Anti-ribosomal-P antibodies are linked to neuropsychiatric manifestations of SLE, most commonly affective disorders and psychosis, although several studies have not found an association and clinical utility remains questionable. 31, 32 Of interest, however, are the results of a study in a mouse model, in which intraventricular injection of anti-ribosomal-P antibodies induced depressive behavior, with histologic staining of the antibody in limbic structures. 33 As mentioned above, several studies have linked the presence of anti-phospholipid antibodies to neuropsychiatric manifestations of SLE, and specifically to NCI. In the CNS, antiphospholipid antibodies might promote microthrombi and noninflammatory vasculopathy, resulting in ischemic damage. 14, 34 Many adults and children with SLE, however, have circulating anti-phospholipid antibodies without evidence of NCI or other neuropsychiatric manifestations. Moreover, whether therapy with warfarin, heparin or aspirin has a role in the prevention or treatment of NCI in SLE is not clear.
Recent attention has focused on anti-NR2 antibodies, a class of antibodies against doublestranded DNA that cross-react with the neuronal N-methyl-d-aspartate receptor subunit, NR2. In a mouse model, these antibodies induced noninflammatory, excitatory neuronal damage, but required a breach in the blood-brain barrier to exert their effect. 35, 36 Studies of anti-NR2 antibodies in adults and children with SLE, however, have yielded mixed results, with the strongest correlations found when anti-NR2 antibodies were detected in the CSF. [36] [37] [38] These conflicting results could reflect the fact that most studies assessed anti-NR2 antibodies only in the peripheral blood, making it impossible to discern whether or not the requisite breach in the blood-brain barrier had occurred.
In addition to circulating autoantibodies, intrathecal expression of cytokines and chemokines could affect the development of NCI and other neuropsychiatric manifestations of SLE. Among the potential mediators of neuronal damage and disease are the cytokines interleukin-6 and interleukin-8, and the chemokines CCL5 (also known as RANTES), CX 3 CL1 (also known as fractalkine), CCL2 (also known as MCP-1) and CXCL9 (also known as MIG). 39, 40 
DIAGNOSING NCI IN PEDIATRIC PATIENTS wITH SLE
The diagnosis of NCI in the context of pediatric SLE remains a clinical one, relying upon a comprehensive medical history, physical examination and formal neuropsychological testing. Other potentially reversible factors might influence cognitive function, including seizures, psychiatric disorders, learning disorders, medications, illicit drug use, infection, metabolic derangement, pain, sleep deprivation, psychosocial stressors and structural brain abnormalities. A detailed school history can provide clues as to the presence of NCI in pediatric patients with SLE. Given the challenges in detecting cognitive abnormalities in both children and adults with SLE, formal neuropsychological assessment is warranted whenever cognitive decline is suspected. Indeed, www.nature.com/clinicalpractice/rheum some argue that all children with SLE should undergo formal neurocognitive assessment at diagnosis to establish a baseline level of cognitive function. In addition, clinical assessment by a psychologist to identify mood and attention disorders is recommended. The assessment of cognition in the constraints of a clinic visit is challenging, and has not been extensively studied in children and adolescents with SLE. Self, teacher and parent reports of cognitive difficulties can be helpful, but are unreliable in establishing a diagnosis. The 21-item Cognitive Symptoms Inventory Questionnaire has been used in adults with SLE, but its specific role in assessing NCI remains unclear and it has not been validated in children or adolescents with SLE. 41 The Mini Mental State Exam (MMSE) can screen for NCI in children aged 4 years and older, but has not been studied as a specific screening tool for NCI in SLE. 42 Although a wide array of instruments is available for formal neurocognitive testing, no standardized battery has yet been validated for the pediatric SLE population. The inherent developmental changes that occur in children and adolescents make neurocognitive testing in this population hard to administer effectively and interpret appropriately. An adult-oriented testing battery proposed by the American College of Rheumatology might be appropriate for older adolescents (Box 2), but this battery includes instruments known to be inappropriate for use in younger children. As a result, members of an ad-hoc working group of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) SLE subcommittee proposed a standardized core set of neuropsychological tests for the assessment of cognitive function in children and adolescents aged 9-18 years based on their experience, a literature search and consensus opinion. 43 The CARRA Neuropsychological Assessment Core Set has not yet been validated or formally tested, but the selected instruments assess the major cognitive domains, including attention, visual and verbal memory, visuomotor skills and psychomotor speed (Table 1 ). For cognitive testing in both adults and children, the general consensus is that a score of two standard deviations below the mean on at least one of the five key cognitive domains represents cognitive impairment. 44 Although a full battery of neuropsychological testing provides comprehensive and useful information, it takes several hours to administer, is expensive, and might not be covered by a patient's medical insurance. In addition, assessment of neurocognitive function in children and adolescents could be hampered by developmental variability, a lack of appropriate controls and limited information about premorbid functioning. Further limitations, which apply to all neurocognitive testing approaches, include language and cultural differences and the potential for score inflation via 'learning effects' after repetitive testing. In addition, children and adolescents tend to have shorter attention spans and are more prone to fatigue than their adult counterparts, thus negatively influencing lengthy testing batteries and threatening the validity of test results. The CARRA core set seeks to address many of these issues by including instruments selected for the broadest age range of pediatric subjects, with attention paid to reducing language barriers, minimizing Although not yet comprehensively validated in pediatric SLE, computer-administered neurocognitive assessment is a promising tool. The most commonly used instrument is the Automated Neuropsychological Assessment Metrics (ANAM), a computerized testing battery developed by the US military in the 1980s. ANAM does not require pre-existing computer skills, has been validated extensively in healthy adults and clinical populations (including SLE) in both English and Spanish, is sensitive to change and can be completed in 20-45 min. 45, 46 The use of ANAM has been validated in adults with SLE, producing results that are comparable with traditional neuropsychological batteries. 47, 48 The Pediatric Automated Neuropsychological Assessment Metrics (Ped-ANAM) has been used in children with SLE aged 10 years or over, but has not yet been compared with standard paper batteries. 4 The Ped-ANAM was adapted from the original ANAM to simplify some of the tasks; however, the stimuli presented are almost identical to the traditional ANAM. Although the Ped-ANAM offers a more time-and cost-efficient alternative for the diagnosis of NCI in the context of pediatric SLE than the current options, it requires further study before it can be recommended as a clinical tool.
Neuroimaging
Neuroimaging can be a useful part of the initial assessment when NCI or other neuropsychiatric manifestations are suspected following clinical evaluation in children and adolescents with SLE. Although structural abnormalities are usually detected on routine CT and MRI, other potentially useful techniques include functional MRI, PET, single photon emission CT (SPECT) and magnetization transfer imaging (MTI).
CT of the brain is useful in emergency settings to exclude cerebral hemorrhage, large infarct or a mass, but rarely has a role in the assessment of NCI. However, conventional MRI sequencing of the brain, including spin-echo T 2 -weighted imaging and fluid-attenuated inversion recovery (FLAIR), is a technique that is widely used for evaluating neuropsychiatric SLE in children and adults.
Most research studies have assessed the use of MRI in heterogeneous populations of adult or pediatric patients with neuropsychiatric manifestations of SLE, rather than specifically focusing on NCI. These studies have identified diffuse cerebral atrophy, small cortical infarcts and nonspecific foci of increased signal in gray and white matter on T 2 -weighted images, but the clinical significance of these findings is often unclear. 49, 50 In one small study of adults with SLE, individuals with cognitive impairment had more cerebral atrophy and larger T 2 -weighted lesions than SLE patients with normal cognitive abilities. 51 Other studies, however, have not found significant associations between specific MRI findings and cognitive function in SLE. 52 No published studies have formally addressed conventional MRI findings and cognitive function in children and adolescents. Diffusion-weighted imaging and diffusion tensor imaging are used to detect the motion of water molecules through neural tissue, thus providing more detailed assessment of neural pathways crucial to cognition.
Although not yet studied extensively, these modalities might allow detailed assessments of white-matter structure and integrity in patients with NCI. CT and magnetic resonance angiography have only a small role in the assessment of NCI in SLE. Vasculopathy, if present, involves small vessels that are not detectable by these modalities. If vasculopathy is strongly suspected, conventional arteriography might be the best option; however, this technique might fail to detect changes in the smallest vessels. PET is used to measure cerebral blood flow, glucose uptake and oxygen consumption in the brain. Primarily in the setting of adult SLE, PET can identify areas of hypometabolism, most often in the parietal or frontal lobes. These findings, however, are not specific for NCI and can be seen in patients with SLE and no neuropsychiatric manifestations. 53, 54 SPECT also measures cerebral blood flow. Although SPECT scans in patients with neuropsychiatric manifestations of SLE are often abnormal, correlations specifically with NCI have been inconsistent. 55, 56 Given the high sensitivity and unclear specificity of both PET and SPECT, these modalities require further study, and the results should be interpreted with caution.
Proton magnetic resonance spectroscopy (MRS), a noninvasive technique that measures biochemical metabolites in the brain, is a promising imaging modality. Preliminary studies of MRS in patients with neuropsychiatric SLE suggest that decreased levels of N-acetyl aspartate, a neuronal marker, and increased choline:creatine ratio, a marker of the glial and neuron transport system, correlate with cognitive abnormalities in adult SLE. 57, 58 MTI is another MRI technique that quantifies alterations in the properties of water protons and other magnetic nuclei as they change physical state or chemical configuration. Although studied most extensively in multiple sclerosis, correlations have been shown between abnormalities in MTI and active neuropsychiatric SLE or SLE-related NCI. [59] [60] [61] [62] To date, neither MRS nor MTI have been studied in children or adolescents with SLE.
Functional MRI allows the assessment of brain activation patterns in response to specific cognitive tasks. Small studies have demonstrated abnormal functional MRI in both adults and children with SLE, suggesting that further study of this modality is warranted. 63 
Laboratory assessment
Laboratory evaluation is useful for excluding alternative causes of suspected SLE-related NCI, such as infections, medication or illicit drug toxicity, metabolic derangement and endocrinopathy; however, no single laboratory test is diagnostic of NCI or can confirm that SLE is responsible for cognitive problems. As NCI can occur with or without systemic disease activity, the utility of typical markers of SLE activity is unclear. Although anti-neuronal and anti-NR2 antibodies have enjoyed recent enthusiasm, to date neither of these markers has demonstrated a clear role in diagnosing or monitoring NCI in SLE. Several studies have suggested an increased prevalence of anti-cardiolipin or other anti-phospholipid antibodies in patients with NCI. As mentioned above, however, there is no clear evidence that intervening with aspirin or other anticoagulation therapies improves cognitive outcomes.
CSF analysis is necessary to exclude the possibility of infection and to assess for generalized CNS inflammation. The presence of oligoclonal bands in the CSF suggests intrathecal immunoglobulin production consistent with active CNS SLE. Although CSF and serum blood tests might be useful in the assessment of individual patients, there are no current guidelines for their use in adults or children with SLE and suspected NCI.
TREATMENT OF SLE-ASSOCIATED NCI
Little is known about the optimal treatment of NCI in patients with SLE of any age. Immunosuppression is often considered, particularly if
LEvY ET AL. fEbRUARY 2009 vOL 5 nO 2 www.nature.com/clinicalpractice/rheum there is evidence of CNS inflammation. While a longitudinal, observational assessment of adults with SLE suggested that those taking daily aspirin had a reduced incidence of NCI, antiplatelet and anticoagulation therapy have not been studied in a randomized controlled trial, and their role in the management of children and adolescents with NCI remains unclear. 13 A randomized, placebo-controlled study of memantine, an N-methyl-d-aspartate receptor antagonist, in adults with SLE showed no improvements in cognitive function at 12 weeks. 64 A major limitation of this study, however, was that subjects were not required to have anti-NR2 antibodies. Psychological support and educational interventions to maximize memory and function can be important for children and families. 65 
FUTURE DIRECTIONS
Despite the fact that NCI is a common complication of pediatric SLE, surprisingly little is known about its epidemiology, pathogenesis and treatment. The challenges of measuring NCI in the developing child, coupled with inconsistencies in study design and the choice of assessment tools, have hampered research in this area. Data from ongoing longitudinal observational studies of neurocognitive function in pediatric patients with SLE will provide improved epidemiological information on which to formulate and evaluate the multitude of remaining questions. Studies are underway to address the lack of consensus on pediatricspecific neurocognitive outcome measures in order to advance research in this area. These include studies to validate the CARRA Neuropsychological Assessment Core Set, and a larger-scale assessment and validation of the Ped-ANAM for pediatric SLE. The development of sophisticated neuroimaging techniques that can assess microanatomy and function, coupled with better understanding of the precise roles of autoantibodies and cytokines in the pathogenesis of NCI in this setting, will allow for improved detection of disease. Imaging studies will assess MTI and further evaluate functional MRI in this population, and serum anti-NR2 antibodies will be compared with CSF antibody profiles in the search for a useful marker of disease. Ultimately, the development and evaluation of targeted therapies for children and adolescents with SLE-related cognitive impairment will be necessary. 
KEY POINTS

